<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34870541</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>5-6</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Amyotrophic lateral sclerosis associated with a pathological expansion in the <i>ATXN7</i> gene.</ArticleTitle><Pagination><StartPage>470</StartPage><EndPage>472</EndPage><MedlinePgn>470-472</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2021.1998537</ELocationID><Abstract><AbstractText>Spinocerebellar ataxia type 7 (SCA7) is an autosomal dominant hereditary neurodegenerative disease caused by the expansion of a CAG-repeat in the ataxin-7 (<i>ATXN7</i>) gene, usually characterized by progressive cerebellar ataxia and retinal dystrophy. We report the case of a 45-year-old woman presenting with a rapid-onset amyotrophic lateral sclerosis (ALS) phenotype associated with a 39-CAG-repeat expansion in <i>ATXN7</i>. This patient had neither ataxia nor retinal dystrophy, but she had an oculomotor cerebellar syndrome and a family history suggestive of SCA7. In SCA7, shorter expansions may be associated with less severe and incomplete clinical phenotypes, which could explain the patient's phenotype. Unknown genetic and environmental factors may also influence the patient's phenotype. We suggest that a pathological expansion in <i>ATXN7</i> should be considered in cases of ALS-like phenotype, particularly when associated with oculomotor abnormalities or a family history of ataxia or blindness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cluse</LastName><ForeName>Florent</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>ALS Resource and Competence Centre, Pierre Wertheimer&#xa0;Hospital, Hospices Civils de Lyon, Bron, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Electroneuromyography and Neuromuscular Diseases Unit, Pierre Wertheimer Hospital, Hospices Civils de Lyon, Bron, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernard</LastName><ForeName>Emilien</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-3952-9265</Identifier><AffiliationInfo><Affiliation>ALS Resource and Competence Centre, Pierre Wertheimer&#xa0;Hospital, Hospices Civils de Lyon, Bron, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Electroneuromyography and Neuromuscular Diseases Unit, Pierre Wertheimer Hospital, Hospices Civils de Lyon, Bron, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroMyoG&#xe8;ne Institute, CNRS UMR5310, INSERM U1217, University of Lyon I, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strubi-Vuillaume</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Biology and Pathology Centre, University Hospital of Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devos</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-2417-799X</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology, LiCEND, ALS Expert Center, University Hospital of Lille, University of Lille, Lille Neuroscience &amp; Cognition, Inserm U1172, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mouzat</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory of Biochemistry and Molecular Biology, University Hospital of N&#xee;mes, N&#xee;mes, Motoneuron Disease: Pathophysiology and Therapy, INM, University of Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lumbroso</LastName><ForeName>Serge</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Biochemistry and Molecular Biology, University Hospital of N&#xee;mes, N&#xee;mes, Motoneuron Disease: Pathophysiology and Therapy, INM, University of Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Froment Tilikete</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Neuro-ophtalmology and Neuro-cognition Unit, Pierre Wertheimer Hospital, Hospices Civils de Lyon, Bron, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facult&#xe9; de m&#xe9;decine Lyon Est, University of Lyon, Lyon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lyon Neuroscience Research Center, INSERM U1028 CNRS UMR 5292, Team impact, Bron, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thobois</LastName><ForeName>St&#xc9;phane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>ALS Resource and Competence Centre, Pierre Wertheimer&#xa0;Hospital, Hospices Civils de Lyon, Bron, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facult&#xe9; de m&#xe9;decine et de Ma&#xef;eutique Lyon Sud Charles M&#xe9;rieux, University of Lyon, Lyon, France, and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNRS, Institut des Sciences Cognitives Marc Jeannerod, UMR 5229, Bron, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pegat</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALS Resource and Competence Centre, Pierre Wertheimer&#xa0;Hospital, Hospices Civils de Lyon, Bron, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Electroneuromyography and Neuromuscular Diseases Unit, Pierre Wertheimer Hospital, Hospices Civils de Lyon, Bron, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067719">Ataxin-7</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000067719" MajorTopicYN="N">Ataxin-7</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058499" MajorTopicYN="Y">Retinal Dystrophies</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020754" MajorTopicYN="Y">Spinocerebellar Ataxias</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">ataxin-7 gene</Keyword><Keyword MajorTopicYN="N">motor neuron disease</Keyword><Keyword MajorTopicYN="N">polyglutamine expansion.</Keyword><Keyword MajorTopicYN="N">spinocerebellar ataxia type 7</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>6</Day><Hour>12</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34870541</ArticleId><ArticleId IdType="doi">10.1080/21678421.2021.1998537</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>